EAP LEADERSHIP ACADEMY 2025 | LEIPZIG, GERMANY

25-27 September 2025

Refund and Cancellation Policy

EAP Leadership Academy 2025

By registering for the EAP Leadership Academy (25–27 September 2025, Leipzig, Germany), you agree to the following cancellation and refund terms:

Upfront Payment Requirement:

 

A €300 upfront payment is required to confirm your registration and accommodation booking.

Participants who attend the full course will receive a refund on 1 October 2025 as follows:

  • Standard Participants: €150 refund
  • Residents in Training: €225 refund

 

No refund will be granted for partial attendance or early departure.

Cancellation by the Participant:

 

Before 25 May 2025 (4 months before the event): Full refund (€300, minus transaction fees).

Between 26 May – 31 July 2025 (4–8 weeks before the event): €150 refund (€150 retained to cover accommodation commitments).

Between 1 August – 1 September 2025 (8–1 weeks before the event): €75 refund, (€225 retained to cover accommodation commitments).

From 2 September 2025 onwards (less than 4 weeks before the event): No refund (full amount retained).

 

No-shows: No refund will be granted.

Event Cancellation by EAP:

 

  • If EAP cancels the Leadership Academy due to force majeure or other unforeseen circumstances, a full refund will be issued within 7 days of the official cancellation announcement.
 

Places are strictly limited to 30 participaants to ensure an intensive and personalised experience.

Our Supporters

 

The EAP Leadership Academy 2025 is proudly supported by:

Nestlé Nutrition Institute

Increasing the positive impact of nutrition.

Sanofi

Transforming the practice of medicine through breakthrough science.

close menu icon

Your Enquiries Are Welcome

We will respond to you by Email

""
 

Core-MD Project

Coordinating Research and Evidence for Medical Devices (CORE-MD)

New ways to test high-risk medical devices.

 

Manufacturers of medical devices need to test their products before being allowed to market them. Specifically, they require clinical data showing their medical device is safe and efficient. In this context, the EU-funded CORE-MD project will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators. The project will propose how new trial designs can contribute and suggest ways to aggregate real-world data from medical device registries.


It will also conduct multidisciplinary workshops to propose a hierarchy of levels of evidence from clinical investigations, as well as educational and training objectives for all stakeholders, to build expertise in regulatory science in Europe. CORE–MD will translate expert scientific and clinical evidence on study designs for evaluating high-risk medical devices into advice for EU regulators, to achieve an appropriate balance between innovation, safety, and effectiveness. A unique collaboration between medical associations, regulatory agencies, notified bodies, academic institutions, patients’ groups, and health technology assessment agencies, will systematically review methodologies for the clinical investigation of high-risk medical devices, recommend how new trial designs can contribute, and advise on methods for aggregating real-world data from medical device registries with experience from clinical practice The consortium is led by the European Society of Cardiology and the European Federation of National Associations of Orthopaedics and Traumatology, and involves all 33 specialist medical associations that are members of the Biomedical Alliance in Europe.

EAP Representative:

  • BERTHOLD KOLETZKO
Read more